Cost-effectiveness of treatment with etanercept for psoriasis in Sweden

被引：0
|
作者：
Christopher Knight
Josephine Mauskopf
Mats Ekelund
Amitabh Singh
Shiyi Yang
Robert Boggs
机构：
[1] RTI Health Solutions,
[2] Velocity House Business and Conference Centre,undefined
[3] RTI Health Solutions,undefined
[4] Pfizer Inc.,undefined
[5] Pfizer Inc.,undefined
来源：
The European Journal of Health Economics | 2012年 / 13卷
关键词：
Cost-effectiveness; Psoriasis; Etanercept; Adalimumab; Intermittent treatment; QALY; I19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：145 / 156
页数：11
相关论文
共 50 条
  • [31] Cost-effectiveness of infliximab (Remicade) in Sweden
    Kobelt, G
    Jonsson, L
    Lindquist, E
    Eberhardt, K
    [J]. ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S158 - S158
  • [32] The cost-effectiveness of inhaled insulin in Sweden
    Neovius, M.
    Pruz, C.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A231 - A231
  • [33] THE COST-EFFECTIVENESS OF ROFLUMILAST FOR COPD IN SWEDEN
    Engstrom, A.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A494 - A494
  • [34] The cost-effectiveness of lifesaving interventions in Sweden
    Ramsberg, JAL
    Sjoberg, L
    [J]. RISK ANALYSIS, 1997, 17 (04) : 467 - 478
  • [35] The cost-effectiveness of sun, sea and psoriasis
    Browne, R.
    Gee, B.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 38 - 38
  • [36] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN INSTITUTIONAL MARKET IN ECUADOR
    Albuja, M. F.
    Torres, F. G.
    Mould, J.
    Estevez, C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A717 - A717
  • [37] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN
    Guijarro, P.
    Crespo, C.
    Brosa, M.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [38] Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden
    Prutz, C.
    Snedecor, S.
    Botteman, M.
    Trocio, J.
    Weinstein, D.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [39] IRON DEFICIENCY IN SWEDEN-TREATMENT OPTIONS, COST-EFFECTIVENESS AND REIMBURSEMENT
    Glenngard, A. H.
    Borg, S.
    Danielson, B. G.
    Persson, U.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A380 - A380
  • [40] COST-EFFECTIVENESS OF FIDAXOMICIN FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION (CDI) IN SWEDEN
    Van Engen, A.
    Lie, X.
    Noren, T.
    Nordling, S.
    Norgaard, K.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A673 - A674
12345